سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

Login
PapersConferencesJournals

Study of anti-tumoric effects and evaluation of survival before and after treatment with GP2 Her2/neu derived peptide conjugated to liposome containing MPL adjuvant for breast cancer in BALB/c mice model

Publish place: International Conference/Workshop of Inter-Islamic Network on Nanotechnology (INN) on Nanotechnology and Nanomedicine
Publish Year: 1396
Type: Conference paper
Language: English
View: 711

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دانلود نمایند.

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

Export:

Link to this Paper:
https://civilica.com/doc/702298

Document National Code:

NTNM01_043

Index date: 26 February 2018

Study of anti-tumoric effects and evaluation of survival before and after treatment with GP2 Her2/neu derived peptide conjugated to liposome containing MPL adjuvant for breast cancer in BALB/c mice model abstract

Vaccine containing synthetic peptide derived from tumor-associated antigen (TAA) can elicit potent cytotoxic T lymphocyte (CTL) response. The conjugated GP2 to malmide-PEG2000-DSPE with DMPC: DMPG: Chol: DOPE containing Monophosphoryl lipid A (MPL) can induced a significant higher INFγ production. The aim of this study was prophylactic and therapeutic effective of different liposome formulations groups. The result demonstrated that Lip-DOPE-MPL-GP2 decrease tumor sizes and longer survival time in comparison of the other formulations in BALB/c mice TUBO xenograft model.

Study of anti-tumoric effects and evaluation of survival before and after treatment with GP2 Her2/neu derived peptide conjugated to liposome containing MPL adjuvant for breast cancer in BALB/c mice model Keywords:

HER2/neu , GP2 peptide , prophylactic , therapeutic , cytotoxic T lymphocyte , MPL

Study of anti-tumoric effects and evaluation of survival before and after treatment with GP2 Her2/neu derived peptide conjugated to liposome containing MPL adjuvant for breast cancer in BALB/c mice model authors

a Razazan

Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

m Ghahremani

Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

j Behravan

Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

a Arab

Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.